Madrigal Pharmaceuticals (MDGL) News Today $282.32 +2.08 (+0.74%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$282.54 +0.22 (+0.08%) As of 06/10/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MDGL Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Cantor Fitzgerald Weighs in on MDGL FY2026 EarningsMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Madrigal Pharmaceuticals in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal forecasts that the bioJune 10 at 8:56 AM | marketbeat.comRheos Capital Works Inc. Sells 13,000 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Rheos Capital Works Inc. decreased its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 23.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 43,215 shares of the biopharmaceuticaJune 9 at 8:00 AM | marketbeat.comBrokerages Set Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Target Price at $416.33June 9 at 2:23 AM | americanbankingnews.comGAMMA Investing LLC Has $12.95 Million Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)GAMMA Investing LLC raised its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 76,537.3% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 39,085 shares of the biopharmaceutical company's stock after acquiring an additionalJune 7, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) have earned an average recommendation of "Moderate Buy" from the ten brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and nineJune 6, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Has $3.65 Million Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Hennion & Walsh Asset Management Inc. grew its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 11.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 11,009 shares of the biopharmaceuticalJune 5, 2025 | marketbeat.comMadrigal Pharmaceuticals to Present at 46th Annual Goldman Sachs Health Care ConferenceJune 3, 2025 | msn.comMadrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care ConferenceJune 2, 2025 | globenewswire.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 23.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 27,538 shares ofJune 1, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stake Lowered by Ameriprise Financial Inc.Ameriprise Financial Inc. cut its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 77.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,668 shares of the biopharmaceutical company's stockMay 30, 2025 | marketbeat.comAltimmune: Upcoming MASH Data Could Be High Impact For Business Development ActivityMay 29, 2025 | seekingalpha.comCetera Investment Advisers Has $889,000 Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Cetera Investment Advisers grew its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 85.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,882 shares of the biopharmaceutical company'sMay 26, 2025 | marketbeat.comMan Group plc Makes New Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Man Group plc bought a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 8,498 shares of the biopharmaceutical company's stock, vaMay 25, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stake Lowered by Nuveen Asset Management LLCNuveen Asset Management LLC cut its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 12.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 77,869 shares of the biopharmaceutical company's stock afteMay 25, 2025 | marketbeat.comProShare Advisors LLC Boosts Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)ProShare Advisors LLC raised its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 32.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,096 shares of the biopharmaceutical company's stock afterMay 23, 2025 | marketbeat.comWoodline Partners LP Raises Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Woodline Partners LP increased its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 110.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 309,117 shares of the biopharmaceutical companyMay 22, 2025 | marketbeat.comVestal Point Capital LP Raises Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Vestal Point Capital LP lifted its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 216.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,000 shares of the biopharmMay 21, 2025 | marketbeat.comSoleus Capital Management L.P. Makes New $3.36 Million Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Soleus Capital Management L.P. bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,900 shares of the biopharmaceutical company's stock, vMay 21, 2025 | marketbeat.comTema Etfs LLC Makes New Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Tema Etfs LLC bought a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 3,620 shares of the biopharmaceutical company's stock, valued at approximMay 20, 2025 | marketbeat.comRafferty Asset Management LLC Lowers Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Rafferty Asset Management LLC lessened its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 25.8% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 33,123 shares of the biopharmaceutical company's stock afterMay 19, 2025 | marketbeat.comBNP Paribas Financial Markets Sells 2,846 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)BNP Paribas Financial Markets decreased its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 29.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,921 shares of thMay 19, 2025 | marketbeat.comDeutsche Bank AG Sells 5,284 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Deutsche Bank AG lowered its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 10.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,658 shares of the biopharmaceutical company's stoMay 18, 2025 | marketbeat.comIn Search Of A Tailwind, Sailing The Doldrums With Madrigal PharmaceuticalsMay 17, 2025 | seekingalpha.comPolar Capital Holdings Plc Has $42.50 Million Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Polar Capital Holdings Plc lifted its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 37.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 137,720 shaMay 17, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Position Increased by Ensign Peak Advisors IncEnsign Peak Advisors Inc lifted its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 124.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 35,361 shares of the biopharmaceutical company's stock after buying an addiMay 15, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Bought by Bank of America Corp DEBank of America Corp DE raised its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 1.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 217,828 shares of the biopharmaceutical company's stockMay 15, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Janus Henderson Group PLCJanus Henderson Group PLC lessened its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 10.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,208,394 shares of the biopharmaceutical company'sMay 13, 2025 | marketbeat.comFORA Capital LLC Takes $347,000 Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)FORA Capital LLC purchased a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,123 shares of the biopharmaceutical company's stockMay 13, 2025 | marketbeat.comBrevan Howard Capital Management LP Acquires New Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Brevan Howard Capital Management LP purchased a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,001 shares of the biopharmaceuMay 13, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Recommendation of "Moderate Buy" by AnalystsMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the ten research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and nine have iMay 13, 2025 | marketbeat.comMadrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH CirrhosisMay 12, 2025 | msn.comMadrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH CirrhosisMay 10, 2025 | globenewswire.comBridgefront Capital LLC Purchases New Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Bridgefront Capital LLC acquired a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,084 shares of the biopharmaceutical companMay 10, 2025 | marketbeat.comAlgert Global LLC Buys New Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Algert Global LLC purchased a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 9,770 shares of the biopharMay 10, 2025 | marketbeat.comNorthern Trust Corp Raises Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Northern Trust Corp grew its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 5.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 155,883 shares of the biopharmaceutical company'sMay 10, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside PotentialMay 10, 2025 | finance.yahoo.comFirst Trust Advisors LP Acquires 1,352 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)First Trust Advisors LP raised its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 50.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,014 shares of the biopharmaceutical company's stock after purchasing an additiMay 10, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Sells 5,877 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)The Manufacturers Life Insurance Company cut its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 19.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,080 shares ofMay 9, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside PotentialMay 9, 2025 | insidermonkey.comBayesian Capital Management LP Boosts Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Bayesian Capital Management LP grew its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 137.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,573 shares oMay 8, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Has $1.71 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Schonfeld Strategic Advisors LLC decreased its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 88.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 5,525 shares of the biopharmaceutical company's stock after sellingMay 8, 2025 | marketbeat.comMadrigal Pharmaceuticals (MDGL): Among Billionaire John Paulson’s Stocks with Huge Upside PotentialMay 7, 2025 | insidermonkey.comWhat is B. Riley's Estimate for MDGL FY2028 Earnings?Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Research analysts at B. Riley issued their FY2028 earnings per share (EPS) estimates for Madrigal Pharmaceuticals in a research note issued on Thursday, May 1st. B. Riley analyst M. Mamtani expects that the biopharmaceutical company wilMay 7, 2025 | marketbeat.comMadrigal Pharmaceuticals: An Encouraging Start For RezdiffraMay 6, 2025 | seekingalpha.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Posts Quarterly Earnings Results, Beats Expectations By $0.30 EPSMadrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($3.32) earnings per share for the quarter, beating analysts' consensus estimates of ($3.62) by $0.30. The company had revenue of $137.25 million for the quarter, compared to analysts' expectations of $112.79 million. During the same quarter in the prior year, the firm posted ($7.38) earnings per share.May 5, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Bought by ArrowMark Colorado Holdings LLCArrowMark Colorado Holdings LLC increased its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 23.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 199,667 shares of the biopharmaMay 5, 2025 | marketbeat.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Shares Down 4.4% - What's Next?Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 4.4% - Time to Sell?May 5, 2025 | marketbeat.comVoya Investment Management LLC Sells 33,672 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)Voya Investment Management LLC cut its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 77.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,942 shares of the biopharmaceuticaMay 5, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Mariner LLCMariner LLC lowered its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 41.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,746 shares of the biopharmaceutical comMay 4, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call TranscriptMay 3, 2025 | seekingalpha.com Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Email Address MDGL Media Mentions By Week MDGL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MDGL News Sentiment▼1.321.01▲Average Medical News Sentiment MDGL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MDGL Articles This Week▼88▲MDGL Articles Average Week Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Biogen News Today United Therapeutics News Today Incyte News Today Neurocrine Biosciences News Today Exelixis News Today BioMarin Pharmaceutical News Today Exact Sciences News Today Repligen News Today Halozyme Therapeutics News Today Ionis Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MDGL) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MDGL Stock Free MDGL Stock Alerts